RefleXion Announces 28 Scientific Presentations at the AAPM 2023 Annual Meeting

Multiple oral presentations evaluate potential of SCINTIX biology-guided radiotherapy, including accuracy of multi-target delivery

RefleXion Medical, a therapeutic oncology company, today announced that researchers from multiple clinical programs will present new scientific evidence in 28 oral, panel, and poster presentations validating the efficacy and feasibility of the RefleXion® X1 machine with SCINTIX™ biology-guided radiotherapy at the 2023 American Association of Physicists in Medicine (AAPM) Annual Meeting in Houston, July 23-26. The company will also hold multi-target SCINTIX technology interactive demonstrations in booth #501.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230720522866/en/

SCINTIX™ therapy, delivered by the RefleXion® X1, uses emissions from cancer cells created by injecting the patient with a radiopharmaceutical to deliver a radiation dose that continuously and autonomously targets the cancer itself. (Photo: Business Wire)

“As we are on the cusp of treating patients with SCINTIX therapy, we’re extremely gratified to have this significant scientific presence that includes five oral and panel presentations, and a poster designated as a blue-ribbon recipient,” said Sean Shirvani, M.D., chief medical officer of RefleXion. “Several of these presentations detail our successfully completed clinical study that supported our FDA clearance for SCINTIX therapy, while others explore its breakthrough potential in treating multiple moving tumors.”

The following oral and panel presentations highlight some of the new research about the accuracy of multi-target SCINTIX therapy, as well as the high degree of accuracy in achieving the primary endpoint from BIOGUIDE-X, the first-in-human clinical study for SCINTIX therapy. Detailed information on all 28 presentations may be found here.

Oral Presentations and Panels:

Oral: Assessment of the Accuracy of Multi-Target Biology-guided Radiotherapy Delivery, Murat Surucu, Ph.D.

Sunday, July 23, 2:21 pm, Room 362

Panel: Biology-Guided Adaptive Radiotherapy, Nataliya Kovalchuk, Ph.D.

Monday, July 24, 4:35 pm, Room 372

Oral: Patient Specific Quality Assurance Verification of Biology-guided Radiotherapy Plans from the First-in-Human Clinical Trial, Bin Cai, Ph.D

Tuesday, July 25, 10:45 am, Room 372

Oral: Demonstration of in-Silico Biology-Guided Radiotherapy Delivery Using Data Acquired on the First Installation of O-Ring Gantry PET/CT Radiotherapy System, Manoj Narayanan, Ph.D.

Tuesday, July 25, 10:55 am, Room 372

Panel: Adaptive RT on the RefleXion Platform, Murat Surucu, Ph.D.

Wednesday, July 26, 9:15 am, Room 362

RefleXion is also hosting an industry lunch symposium during the AAPM annual meeting at 12:30 PM CDT on July 24. Physicists Murat Surucu, Ph.D., Chunhui Han, Ph.D., and Bin Cai, Ph.D., will share their clinical experience with the X1 and how they are preparing for SCINTIX therapy.

Overcoming the hurdles of targeting and motion management, especially for multiple tumors, is the core challenge in external-beam radiotherapy. SCINTIX therapy, delivered by the RefleXion® X1, uses emissions from cancer cells created by injecting the patient with a radiopharmaceutical to deliver a radiation dose that continuously and autonomously targets the cancer itself. Moreover, this fundamental capability simultaneously lights up all targeted tumors in the body during treatment. SCINTIX technology handles tumor motion from all types of movement, including expected motion from internal processes such as breathing and digestion or unexpected movement by a patient.

About RefleXion Medical

RefleXion is a privately held therapeutic oncology company located in Hayward, Calif., commercializing SCINTIX biology-guided radiotherapy, a novel treatment modality that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery. Granted Breakthrough Device designation for lung tumors and De Novo marketing authorization by the FDA, SCINTIX therapy is indicated for use in lung and bone tumors. These tumors may arise from primary lung and bone cancers or result from metastases to the lungs or bone from other primary cancers. The RefleXion X1 is also cleared for stereotactic body radiotherapy, stereotactic radiosurgery, and intensity modulated radiotherapy for solid tumors located anywhere in the body.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230720522866/en/

“As we are on the cusp of treating patients with SCINTIX therapy, we’re extremely gratified to have this significant scientific presence that includes five oral and panel presentations, and a poster designated as a blue-ribbon recipient.”